Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study

OMERACT-EULAR-Ultrasound Task Force

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

Original languageEnglish
Article numbere000237
JournalRMD Open
Volume2
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Synovitis
Rheumatoid Arthritis
Doppler Ultrasonography
Joints
C-Reactive Protein
Metacarpophalangeal Joint
Abatacept
Advisory Committees
Methotrexate

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept : Results from the APPRAISE study. / OMERACT-EULAR-Ultrasound Task Force.

In: RMD Open, Vol. 2, No. 1, e000237, 2016.

Research output: Contribution to journalArticle

@article{4047f520cc9b464592085a2a51f826bd,
title = "Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study",
abstract = "Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.",
author = "{OMERACT-EULAR-Ultrasound Task Force} and D'Agostino, {Maria Antonietta} and Maarten Boers and Wakefield, {Richard J.} and Hammer, {Hilde Berner} and Olivier Vittecoq and Georgios Filippou and P. B{\'a}lint and Ingrid M{\"o}ller and Annamaria Iagnocco and Esperanza Naredo and Mikkel {\O}stergaard and Corine Gaillez and {Le Bars}, Manuela",
year = "2016",
doi = "10.1136/rmdopen-2015-000237",
language = "English",
volume = "2",
journal = "RMD Open",
issn = "2056-5933",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept

T2 - Results from the APPRAISE study

AU - OMERACT-EULAR-Ultrasound Task Force

AU - D'Agostino, Maria Antonietta

AU - Boers, Maarten

AU - Wakefield, Richard J.

AU - Hammer, Hilde Berner

AU - Vittecoq, Olivier

AU - Filippou, Georgios

AU - Bálint, P.

AU - Möller, Ingrid

AU - Iagnocco, Annamaria

AU - Naredo, Esperanza

AU - Østergaard, Mikkel

AU - Gaillez, Corine

AU - Le Bars, Manuela

PY - 2016

Y1 - 2016

N2 - Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

AB - Objectives: To explore whether changes in a composite ( power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). Methods: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2-5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1-16 evaluations for clinical status and response (Disease Activity Score (DAS) 28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. Results: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2-5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2-5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. Conclusions: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. Trial registration number: NCT00767325; Results.

UR - http://www.scopus.com/inward/record.url?scp=84987962115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987962115&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2015-000237

DO - 10.1136/rmdopen-2015-000237

M3 - Article

AN - SCOPUS:84987962115

VL - 2

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 1

M1 - e000237

ER -